Cargando…

Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy

The concomitant presence of del(5q) and JAK2(V617F) mutation is an infrequent event which occurs in rare patients with peculiar cytogenetic, molecular, morphological and clinical features, resembling those of both myelodysplastic syndromes and myeloproliferative neoplasms. Lenalidomide may induce ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Musto, Pellegrino, Simeon, Vittorio, Guariglia, Roberto, Bianchino, Gabriella, Grieco, Vitina, Nozza, Filomena, La Rocca, Francesco, Marziano, Gioacchino, Lalinga, Anna Vittoria, Fabiani, Emiliano, Voso, Maria Teresa, Scaravaglio, Patrizia, Mecucci, Cristina, D’Arena, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063862/ https://www.ncbi.nlm.nih.gov/pubmed/24966686 http://dx.doi.org/10.2147/OTT.S59628

Ejemplares similares

Case report: Hematologic malignancies concomitant diagnosis of hairy cell leukemia and chronic lymphocytic leukemia: A rare association
por: Valvano, Luciana, et al.
Publicado: (2022)

Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia
por: De Luca, Luciana, et al.
Publicado: (2017)

A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain
por: Nozza, Filomena, et al.
Publicado: (2019)

De Novo and Therapy-Related Myelodysplastic Syndromes: Analogies and Differences
por: Leone, Giuseppe, et al.
Publicado: (2022)

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
por: D'Arena, Giovanni, et al.
Publicado: (2013)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for JAK2 V617F Allele Mutational Burden Assessment in Myeloproliferative Neoplasms: A Retrospective Study
por: La Rocca, Francesco, et al.
Publicado: (2020)

Comparative analyses of DNA extraction methods for whole blood quantification of HCMV DNAemia in patients with hematological diseases: false negative cases in manual method
por: Bianchino, Gabriella, et al.
Publicado: (2023)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

Monoclonal B-Cell Lymphocytosis
por: D’Arena, G., et al.
Publicado: (2014)

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
por: Ebert, Benjamin L, et al.
Publicado: (2008)

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes
por: Giagounidis, Aristoteles A N, et al.
Publicado: (2007)

Reversal of T-cell Tolerance in Myelodysplastic Syndrome through Lenalidomide Immune Modulation
por: McDaniel, Jessica M., et al.
Publicado: (2011)

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count
por: Divoux, Marion, et al.
Publicado: (2020)

Correlation analysis between auto-immunological and mutational profiles in myelodysplastic syndromes
por: Cristiano, Antonio, et al.
Publicado: (2023)

New Treatments for Myelodysplastic Syndromes
por: D’Alò, Francesco, et al.
Publicado: (2010)

Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow Cytometry
por: Statuto, Teodora, et al.
Publicado: (2020)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)
por: Kurtin, Sandra E., et al.
Publicado: (2017)

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2020)

Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
por: Butrym, Aleksandra, et al.
Publicado: (2015)

Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors
por: McGraw, Kathy L., et al.
Publicado: (2014)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

Rituximab and lenalidomide combination treatment for rheumatoid arthritis complicated with myelodysplastic syndrome: A case report
por: Evangelatos, Gerasimos, et al.
Publicado: (2017)

Fournier’s Gangrene Complicating Hematologic Malignancies: a Case Report and Review of Licterature
por: D’Arena, Giovanni, et al.
Publicado: (2013)

Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers
por: Laurino, Simona, et al.
Publicado: (2023)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion
por: YANG, YAN, et al.
Publicado: (2013)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome
por: Pham, Brian, et al.
Publicado: (2021)

Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
por: Hong, Junshik, et al.
Publicado: (2021)

Endothelial Progenitor Cell Dysfunction in Myelodysplastic Syndromes: Possible Contribution of a Defective Vascular Niche to Myelodysplasia()()
por: Teofili, Luciana, et al.
Publicado: (2015)

Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias
por: Leone, Giuseppe, et al.
Publicado: (2008)

Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!
por: Al-Jafar, Hassan A., et al.
Publicado: (2012)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
por: Komrokji, R. S., et al.
Publicado: (2016)

Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide
por: Rollison, Dana E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_khl6bctctpdggbu8ke06725pba